Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 18, 2025 08:00 ET | Source: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus

All 27 patients completed treatment with no serious adverse events, underscoring a favorable safety profileStatistically significant improvements achieved across all efficacy endpoints at the 4-week...
June 25, 2025 15:15 ET | Source: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting

Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting
June 20, 2025 15:19 ET | Source: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market

Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market
June 17, 2025 08:30 ET | Source: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology

Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology
June 04, 2025 08:30 ET | Source: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development
May 15, 2025 09:00 ET | Source: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting

Lipella Pharmaceuticals to Present Phase 2a Data for LP-10 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting
April 23, 2025 08:30 ET | Source: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference
April 22, 2025 05:30 ET | Source: Lipella Pharmaceuticals Inc.

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025
April 08, 2025 05:00 ET | Source: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus
March 31, 2025 11:00 ET | Source: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast

Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast